Streptococcal Pharyngitis

Infectious Disease MONDO:0021783 Pathograph 20 Show in embeddings browser Bacterial infection

Streptococcal pharyngitis is an acute group A Streptococcus upper-airway infection in which Streptococcus pyogenes adheres to and colonizes the pharyngeal and tonsillar epithelium, causing abrupt pharyngeal inflammation with fever, throat pain, odynophagia, and tender anterior cervical lymphadenopathy. Untreated infection can spread contiguously or seed post-streptococcal immune sequelae, motivating throat-swab confirmation and prompt narrow-spectrum antibiotic treatment.

Ask OpenScientist

Ask a research question about Streptococcal Pharyngitis. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

7
Pathophys.
10
Phenotypes
20
Pathograph
3
Medical Actions
1
Deep Research
🏷

Classifications

Harrison's Part
INFECTIOUS DISEASES
⚙

Pathophysiology

7
Streptococcal Pharyngeal Adhesion and Colonization
Streptococcus pyogenes uses surface adhesins and pili to attach to and colonize pharyngeal and tonsillar epithelial surfaces, establishing the mucosal infection that initiates group A streptococcal pharyngitis.
pharyngeal and tonsillar epithelial cell CL:0000066 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves pharyngeal and tonsillar epithelial cell, annotated with epithelial cell (CL:0000066). CL:0000066 is a cell type from the Cell Ontology.
adhesion of symbiont to host GO:0044406 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves adhesion of symbiont to host (GO:0044406). GO:0044406 is a biological process from the Gene Ontology. response to bacterium GO:0009617 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal response to bacterium (GO:0009617). GO:0009617 is a biological process from the Gene Ontology. ⚠ ABNORMAL
pharynx UBERON:0006562 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in pharynx (UBERON:0006562). UBERON:0006562 is an anatomical location from the Uberon multi-species anatomy ontology. tonsil UBERON:0002372 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in tonsil (UBERON:0002372). UBERON:0002372 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
SpeA-Mediated Tonsillar Immune Dysregulation Toxigenic strains can express SpeA superantigen in the tonsillar niche.
Acute Pharyngotonsillar Inflammation Mucosal GAS colonization triggers the acute local inflammatory syndrome.
Show evidence (2 references)
PMID:27312939 SUPPORT Other
"The upper respiratory tract and skin are major reservoirs for GAS infections. The ability of GAS to establish an infection in the new host at these anatomical sites primarily results from two distinct physiological processes, namely bacterial adhesion and colonization."
This supports epithelial adhesion and colonization as the initiating steps at GAS mucosal reservoirs.
PMID:33623073 SUPPORT BACKGROUND Other
"Pili of Group A Streptococcus (GAS) are surface-exposed structures involved in adhesion and colonisation of the host during infection. The major protein component of the GAS pilus is the T-antigen, which multimerises to form the pilus shaft."
This supports GAS pili and T-antigen as surface adhesins that contribute to host colonization.
SpeA-Mediated Tonsillar Immune Dysregulation
Streptococcal pyrogenic exotoxin A and related superantigens can drive proliferation of human tonsillar T cells, alter T follicular helper-cell phenotype, and induce B-cell apoptosis with reduced immunoglobulin release, providing superantigen-producing organisms with a local survival advantage.
tonsillar T cell CL:0000084 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves tonsillar T cell, annotated with T cell (CL:0000084). CL:0000084 is a cell type from the Cell Ontology. tonsillar B cell CL:0000236 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves tonsillar B cell, annotated with B cell (CL:0000236). CL:0000236 is a cell type from the Cell Ontology.
T cell activation GO:0042110 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased T cell activation (GO:0042110). GO:0042110 is a biological process from the Gene Ontology. ↑ INCREASED B-cell apoptotic process GO:0006915 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased B-cell apoptotic process, annotated with apoptotic process (GO:0006915). GO:0006915 is a biological process from the Gene Ontology. ↑ INCREASED
tonsil UBERON:0002372 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in tonsil (UBERON:0002372). UBERON:0002372 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Acute Pharyngotonsillar Inflammation SpeA-stimulated tonsil T cells release proinflammatory cytokines.
Show evidence (1 reference)
PMID:30815853 SUPPORT In Vitro
"Tonsil T cells proliferated in response to SpeA and demonstrated typical release of proinflammatory cytokines. When cultured in the absence of superantigen, tonsil preparations released large quantities of immunoglobulin over 7 days. In contrast, marked B cell apoptosis and abrogation of total..."
This human tonsil-cell experiment directly supports SpeA-driven T-cell activation and B-cell death in the tissue affected by GAS tonsillopharyngitis.
Acute Pharyngotonsillar Inflammation
Infection-induced inflammation of the pharynx, tonsils, uvula, and draining anterior cervical lymph nodes accounts for the characteristic abrupt fever, sore throat, odynophagia, pharyngitis, and tender anterior cervical lymphadenopathy of streptococcal pharyngitis.
inflammatory response GO:0006954 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased inflammatory response (GO:0006954). GO:0006954 is a biological process from the Gene Ontology. ↑ INCREASED
pharynx UBERON:0006562 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in pharynx (UBERON:0006562). UBERON:0006562 is an anatomical location from the Uberon multi-species anatomy ontology. tonsil UBERON:0002372 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in tonsil (UBERON:0002372). UBERON:0002372 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Pharyngitis Pharyngeal inflammation produces the defining pharyngitis.
Enlarged tonsils Tonsillar inflammation produces tonsillar enlargement.
Tonsillar exudate Pharyngotonsillar inflammation can produce tonsillar exudate.
Pharyngalgia Local inflammation produces intense throat pain.
Odynophagia Throat inflammation produces pain on swallowing.
Fever GAS pharyngitis produces abrupt systemic fever.
Cervical lymphadenopathy Regional immune activation enlarges tender anterior cervical lymph nodes.
Contiguous Suppurative Spread Local spread can produce otitis media, sinusitis, and other suppurative complications.
Post-Streptococcal Immune Sequelae A subset of infections can trigger autoimmune sequelae after the acute pharyngeal infection.
Show evidence (1 reference)
PMID:37493159 SUPPORT Other
"Children with GABHS pharyngitis typically present with an abrupt onset of fever, intense pain in the throat, pain on swallowing, an inflamed pharynx, enlarged and erythematous tonsils, a red and swollen uvula, enlarged tender anterior cervical lymph nodes."
This clinical review links acute GABHS pharyngitis to the local pharyngotonsillar inflammatory findings and systemic fever.
Contiguous Suppurative Spread
Local extension from group A streptococcal pharyngitis can produce suppurative complications, including otitis media, sinusitis, mastoiditis, and peritonsillar or retropharyngeal abscess.
inflammatory response GO:0006954 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased inflammatory response (GO:0006954). GO:0006954 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Otitis media Contiguous spread can produce acute middle-ear infection.
Sinusitis Contiguous spread can produce acute sinusitis.
Peritonsillar abscess Local suppurative spread can produce quinsy.
Show evidence (1 reference)
PMID:23067784 SUPPORT BACKGROUND Human Clinical
"Complications associated to group-A streptococcal pharyingitis include non-suppurative complications such as acute rheumatic fever and glomerulonephritis and suppurative complications such as peritonsillar or retropharyngeal abscess, sinusitis, mastoiditis, otitis media, meningitis, brain..."
This case report and literature review supports otitis media and sinusitis as recognized suppurative complications of GAS pharyngitis.
Post-Streptococcal Immune Sequelae
Group A Streptococcus can trigger post-infectious immune complications after pharyngitis, including acute rheumatic fever, acute post-streptococcal glomerulonephritis, and rheumatic heart disease.
immune response GO:0006955 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal immune response (GO:0006955). GO:0006955 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Show evidence (1 reference)
PMID:40572286 SUPPORT Other
"GAS also notably triggers post-infectious immune sequelae, including acute poststreptococcal glomerulonephritis (APSGN), acute rheumatic fever (ARF), and rheumatic heart disease (RHD), which are major health burdens, especially in low-income countries."
This review supports post-streptococcal immune disease as a downstream branch of GAS infection without re-curating those distinct sequelae here.
Streptococcal Peptidoglycan Cross-Linking
Streptococcus pyogenes depends on penicillin-binding-protein transpeptidation to cross-link its peptidoglycan cell wall; beta-lactam antibiotics inhibit this reaction and group A Streptococcus remains universally susceptible to penicillin.
Peptidoglycan-Based Cell Wall Biogenesis GO:0009273 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves Peptidoglycan-Based Cell Wall Biogenesis (GO:0009273). GO:0009273 is a biological process from the Gene Ontology.
Show evidence (1 reference)
PMID:39259691 SUPPORT Other
"GAS remains universally susceptible to penicillin but there are increasing reports of macrolide and lincosamide resistance, particularly in invasive isolates, with uncertain clinical consequences."
Universal penicillin susceptibility supports cell-wall beta-lactams as an active therapeutic vulnerability in GAS.
Streptococcal Ribosomal Translation
Streptococcus pyogenes depends on 70S-ribosome translation. Clindamycin and macrolides target the 50S ribosome and are treatment alternatives for immediate-type penicillin hypersensitivity.
Translation GO:0006412 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves Translation (GO:0006412). GO:0006412 is a biological process from the Gene Ontology.
Show evidence (1 reference)
PMID:12860123 SUPPORT In Vitro
"The macrolide-lincosamide-streptogramin B class (MLS) of antibiotics contains structurally different but functionally similar drugs, that all bind to the 50S ribosomal subunit. It has been suggested that these compounds block the path by which nascent peptides exit the ribosome. We have studied..."
This cell-free ribosome study supports 50S binding and peptide-exit blockade by the macrolide and lincosamide drug classes represented by this node.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Streptococcal Pharyngitis Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

10
Cardiovascular 2
Enlarged tonsils HP:0030812 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Enlarged tonsils (HP:0030812). HP:0030812 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37493159 SUPPORT Other
"Children with GABHS pharyngitis typically present with an abrupt onset of fever, intense pain in the throat, pain on swallowing, an inflamed pharynx, enlarged and erythematous tonsils, a red and swollen uvula, enlarged tender anterior cervical lymph nodes."
This supports enlarged tonsils as a presenting local inflammatory sign.
Cervical lymphadenopathy HP:0025289 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cervical lymphadenopathy (HP:0025289). HP:0025289 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37493159 SUPPORT Other
"Children with GABHS pharyngitis typically present with an abrupt onset of fever, intense pain in the throat, pain on swallowing, an inflamed pharynx, enlarged and erythematous tonsils, a red and swollen uvula, enlarged tender anterior cervical lymph nodes."
This supports tender anterior cervical lymphadenopathy.
Digestive 1
Odynophagia HP:0032043 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Odynophagia (HP:0032043). HP:0032043 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37493159 SUPPORT Other
"Children with GABHS pharyngitis typically present with an abrupt onset of fever, intense pain in the throat, pain on swallowing, an inflamed pharynx, enlarged and erythematous tonsils, a red and swollen uvula, enlarged tender anterior cervical lymph nodes."
This supports pain on swallowing in the clinical presentation.
Ear 1
Otitis media HP:0000388 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Otitis media (HP:0000388). HP:0000388 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:17054126 SUPPORT Other
"Suppurative complications: Antibiotics reduced the incidence of acute otitis media (RR 0.30; 95% CI 0.15 to 0.58); of acute sinusitis (RR 0.48; 95% CI 0.08 to 2.76); and of quinsy (peritonsillar abscess) compared to those taking placebo (RR 0.15; 95% CI 0.05 to 0.47)."
This Cochrane review supports otitis media as a suppurative complication tracked in sore-throat antibiotic trials.
Head and Neck 1
Sinusitis HP:0000246 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Sinusitis (HP:0000246). HP:0000246 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:17054126 SUPPORT Other
"Suppurative complications: Antibiotics reduced the incidence of acute otitis media (RR 0.30; 95% CI 0.15 to 0.58); of acute sinusitis (RR 0.48; 95% CI 0.08 to 2.76); and of quinsy (peritonsillar abscess) compared to those taking placebo (RR 0.15; 95% CI 0.05 to 0.47)."
This Cochrane review supports acute sinusitis as a suppurative complication tracked in sore-throat antibiotic trials.
Metabolism 1
Fever HP:0001945 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Fever (HP:0001945). HP:0001945 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37493159 SUPPORT Other
"Children with GABHS pharyngitis typically present with an abrupt onset of fever, intense pain in the throat, pain on swallowing, an inflamed pharynx, enlarged and erythematous tonsils, a red and swollen uvula, enlarged tender anterior cervical lymph nodes."
This supports abrupt fever as a presenting manifestation.
Respiratory 2
Pharyngitis HP:0025439 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Pharyngitis (HP:0025439). HP:0025439 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37493159 SUPPORT Other
"Children with GABHS pharyngitis typically present with an abrupt onset of fever, intense pain in the throat, pain on swallowing, an inflamed pharynx, enlarged and erythematous tonsils, a red and swollen uvula, enlarged tender anterior cervical lymph nodes."
This supports pharyngeal inflammation as a presenting manifestation of GABHS pharyngitis.
Tonsillar exudate Pharyngeal exudate HP:0034035 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Tonsillar exudate, annotated with Pharyngeal exudate (HP:0034035). HP:0034035 is a phenotype from the Human Phenotype Ontology.
HPO has HP:0034035 for pharyngeal exudate but no tonsil-specific exudate term: `runoak -i ols:hp search "l~tonsillar"` returned no candidate, and `runoak -i ols:hp search "l~exudate"` returned HP:0034035 as the only upper-airway exudate term.
Show evidence (1 reference)
PMID:34535115 SUPPORT Human Clinical
"Both cough and coryza were more common in patients with only viruses (67%) than in patients with only bacteria (21%) (p < 0.001), whereas tonsillar coating was more common in patients with only bacteria (53%) than in patients with only viruses (29%) (p = 0.006)."
This prospective pharyngotonsillitis study supports tonsillar coating as a bacterial-enriched local finding.
Constitutional 1
Pharyngalgia HP:0033050 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Sore throat, annotated with Pharyngalgia (HP:0033050). HP:0033050 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37493159 SUPPORT Other
"Children with GABHS pharyngitis typically present with an abrupt onset of fever, intense pain in the throat, pain on swallowing, an inflamed pharynx, enlarged and erythematous tonsils, a red and swollen uvula, enlarged tender anterior cervical lymph nodes."
This supports intense throat pain as a symptom of GABHS pharyngitis; HPO lists Sore throat as an exact synonym of Pharyngalgia.
Other 1
Peritonsillar abscess
No HPO term is bound because `runoak -i ols:hp search "l~peritonsillar"` and `runoak -i ols:hp search "l~quinsy"` returned no candidate terms.
Show evidence (1 reference)
PMID:17054126 SUPPORT Other
"Suppurative complications: Antibiotics reduced the incidence of acute otitis media (RR 0.30; 95% CI 0.15 to 0.58); of acute sinusitis (RR 0.48; 95% CI 0.08 to 2.76); and of quinsy (peritonsillar abscess) compared to those taking placebo (RR 0.15; 95% CI 0.05 to 0.47)."
This Cochrane review supports quinsy as a suppurative complication tracked in sore-throat antibiotic trials.
💊

Medical Actions

3
Beta-lactam antibiotic therapy
Action: antimicrobial agent therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is antimicrobial agent therapy, annotated with Antibiotic Therapy (NCIT:C15620). NCIT:C15620 is a clinical intervention from the NCI Thesaurus. Ontology label: Antibiotic Therapy NCIT:C15620
Agent: penicillin CHEBI:17334 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses penicillin (CHEBI:17334). CHEBI:17334 is a therapeutic agent from Chemical Entities of Biological Interest. amoxicillin CHEBI:2676 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses amoxicillin (CHEBI:2676). CHEBI:2676 is a therapeutic agent from Chemical Entities of Biological Interest. benzathine penicillin G CHEBI:756117 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses benzathine penicillin G, annotated with penicillin g benzathine (CHEBI:756117). CHEBI:756117 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Small molecule
Penicillin or amoxicillin treats confirmed group A streptococcal pharyngitis by targeting streptococcal peptidoglycan cross-linking, while effective microbiologic treatment also provides primary prevention of acute rheumatic fever.
Mechanism Target:
Streptococcal Peptidoglycan Cross-Linking — Beta-lactams inhibit the penicillin-binding-protein transpeptidation needed for peptidoglycan cross-linking in GAS.
Post-Streptococcal Immune Sequelae — Prompt antibiotic treatment of streptococcal pharyngitis prevents many acute rheumatic fever episodes.
Target Phenotypes: Pharyngitis HP:0025439 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Pharyngitis (HP:0025439). HP:0025439 is a phenotype from the Human Phenotype Ontology. Fever HP:0001945 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Fever (HP:0001945). HP:0001945 is a phenotype from the Human Phenotype Ontology. Sore throat HP:0033050 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Sore throat, annotated with Pharyngalgia (HP:0033050). HP:0033050 is a phenotype from the Human Phenotype Ontology.
Show evidence (4 references)
PMID:37493159 SUPPORT Other
"Antimicrobial therapy should be initiated without delay once the diagnosis is confirmed. Oral penicillin V and amoxicillin remain the drugs of choice."
This supports penicillin and amoxicillin as first-line therapy for confirmed GABHS pharyngitis.
PMID:22691611 SUPPORT Other
"Antibiotic therapy is recommended in microbiologically documented GABHS pharyngitis. Because penicillin V is not available in Italy, amoxicillin (50 mg/kg/d in 2-3 doses orally) for 10 days is the first choice of treatment. In noncompliant cases, benzathine penicillin may be administered."
This national-guideline summary supports amoxicillin treatment for documented GABHS pharyngitis and intramuscular benzathine penicillin for patients who may not complete oral therapy.
PMID:41956705 SUPPORT BACKGROUND Human Clinical
"Detection and treatment of streptococcal pharyngitis in children reduces acute rheumatic fever by 70-80%."
This supports antibiotic treatment of streptococcal pharyngitis as primary prevention for acute rheumatic fever.
+ 1 more reference
Antipyretic and analgesic symptom relief
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: ibuprofen CHEBI:5855 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses ibuprofen (CHEBI:5855). CHEBI:5855 is a therapeutic agent from Chemical Entities of Biological Interest. paracetamol CHEBI:46195 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses paracetamol (CHEBI:46195). CHEBI:46195 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Small molecule
Ibuprofen or paracetamol can be used to relieve fever and painful sore throat discomfort during acute pharyngitis.
Target Phenotypes: Fever HP:0001945 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Fever (HP:0001945). HP:0001945 is a phenotype from the Human Phenotype Ontology. Sore throat HP:0033050 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Sore throat, annotated with Pharyngalgia (HP:0033050). HP:0033050 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:22691611 SUPPORT Other
"Ibuprofen or paracetamol is recommended for relief of pain or fever associated with discomfort."
This guideline supports NSAID or paracetamol symptom relief for painful or febrile acute pharyngitis.
Alternative antibiotics for penicillin allergy
Action: antimicrobial agent therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is antimicrobial agent therapy, annotated with Antibiotic Therapy (NCIT:C15620). NCIT:C15620 is a clinical intervention from the NCI Thesaurus. Ontology label: Antibiotic Therapy NCIT:C15620
Agent: cephalosporin CHEBI:23066 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses cephalosporin (CHEBI:23066). CHEBI:23066 is a therapeutic agent from Chemical Entities of Biological Interest. clindamycin CHEBI:3745 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses clindamycin (CHEBI:3745). CHEBI:3745 is a therapeutic agent from Chemical Entities of Biological Interest. azithromycin CHEBI:2955 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses azithromycin (CHEBI:2955). CHEBI:2955 is a therapeutic agent from Chemical Entities of Biological Interest. clarithromycin CHEBI:3732 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses clarithromycin (CHEBI:3732). CHEBI:3732 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Small molecule
Cephalosporins can be used for non-anaphylactic penicillin allergy, while clindamycin and macrolides are alternatives for immediate-type penicillin hypersensitivity.
Mechanism Target:
Streptococcal Peptidoglycan Cross-Linking — Cephalosporins retain the beta-lactam PBP target.
Streptococcal Ribosomal Translation — Clindamycin and macrolides target the bacterial ribosome.
Target Phenotypes: Pharyngitis HP:0025439 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Pharyngitis (HP:0025439). HP:0025439 is a phenotype from the Human Phenotype Ontology. Sore throat HP:0033050 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Sore throat, annotated with Pharyngalgia (HP:0033050). HP:0033050 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37493159 SUPPORT Other
"For patients who have a non-anaphylactic allergy to penicillin, oral cephalosporin is an acceptable alternative. For patients with a history of immediate, anaphylactic-type hypersensitivity to penicillin, oral clindamycin, clarithromycin, and azithromycin are acceptable alternatives."
This supports cephalosporin, clindamycin, azithromycin, and clarithromycin alternatives for patients with penicillin allergy.
🔬

Diagnosis

2
Throat swab microbiologic testing
Suspected group A streptococcal pharyngitis is confirmed with throat-swab microbiologic testing, such as culture, rapid antigen detection testing, or molecular point-of-care testing.
diagnostic procedure NCIT:C18020 NCI Thesaurus (NCIT)
Results: Detection of group A Streptococcus from a throat swab supports the diagnosis in a compatible clinical syndrome.
A positive swab alone does not establish active disease when it reflects asymptomatic carriage, so testing and treatment are framed around a compatible clinical syndrome.
Show evidence (2 references)
PMID:37493159 SUPPORT Other
"Patients suspected of having GABHS pharyngitis should be confirmed by microbiologic testing (e.g., culture, rapid antigen detection test, molecular point-of-care test) of a throat swab specimen prior to the initiation of antimicrobial therapy."
This supports throat-swab microbiologic confirmation before antibiotic therapy in suspected GABHS pharyngitis.
PMID:22691611 SUPPORT Other
"Because the carrier state is not associated with increased risk of suppurative complications and risk of GABHS transmission to contacts is minimal, the carrier state should never be investigated and treated."
This guideline supports interpreting a positive GABHS test in clinical context rather than investigating asymptomatic carriage as acute disease.
Clinical-score triage
Centor-style clinical scores can use features such as cough absence and tonsillar coating to guide microbiologic testing, but score-only diagnosis is insufficient in children with sore throat.
diagnostic procedure NCIT:C18020 NCI Thesaurus (NCIT)
Results: Centor score alone is not adequate to diagnose or exclude pediatric GAS pharyngitis.
Show evidence (3 references)
PMID:39528865 SUPPORT Human Clinical
"The Centor score alone does not seem to be of any utility in guiding the diagnosis of suspected streptococcal pharyngitis. Microbiological testing remains necessary for accurate diagnosis and CRP should not be used to differentiate viral and bacterial pharyngitis cases."
This pediatric study supports the limitation of clinical-score-only diagnosis and the need for microbiologic testing.
PMID:34535115 SUPPORT Human Clinical
"Tonsillar coating (adjusted OR 6.0; 95% CI 2.5-14) and a lack of cough (adjusted OR 3.5; 95% CI 1.5-8.0) were significantly associated with Streptococcus pyogenes (group A streptococci; GAS) and with any bacterial finding."
This supports tonsillar coating and absence of cough as clinical features that raise the probability of GAS pharyngotonsillitis.
PMID:38182052 SUPPORT Other
"Centor and McIsaac scores are clinical prediction rules for diagnosing group A streptococcus (GAS) infection in patients with pharyngitis. Their recommended thresholds vary between guidelines."
This meta-analysis identifies Centor and McIsaac as GAS pharyngitis triage scores with guideline-dependent thresholds.
🦠

Infectious Agent

1
Streptococcus pyogenes
Streptococcus pyogenes, or group A Streptococcus, is a human-adapted beta-hemolytic coccus that colonizes the upper respiratory tract and can cause acute pharyngitis.
Streptococcus pyogenes NCBITaxon:1314 NCBI Taxonomy (NCBITaxon)
Show evidence (1 reference)
PMID:40572286 SUPPORT Other
"Group A beta-hemolytic Streptococcus (GAS) is a Gram-positive, coccoid-shaped bacterium that tends to grow in chains; it is a non-spore-forming, facultatively anaerobic, catalase-negative, aerobic bacterium. It is known to cause a wide range of infections in children, ranging from mild upper..."
This review identifies group A Streptococcus as the bacterial agent that causes pharyngitis.
↔️

Transmission

1
Close-contact and respiratory-droplet spread
Group A Streptococcus spreads between humans through close or direct contact and especially through respiratory droplets, with the upper respiratory tract serving as a major reservoir.
Show evidence (1 reference)
PMID:27312939 SUPPORT Other
"The main route of GAS transmission between humans is through close or direct physical contact, and particularly via respiratory droplets. The upper respiratory tract and skin are major reservoirs for GAS infections."
This supports close-contact and droplet transmission from upper-airway reservoirs.
{ }

Source YAML

click to show 
name: Streptococcal Pharyngitis
creation_date: "2026-09-27T06:23:39Z"
description: >-
  Streptococcal pharyngitis is an acute group A Streptococcus upper-airway
  infection in which Streptococcus pyogenes adheres to and colonizes the
  pharyngeal and tonsillar epithelium, causing abrupt pharyngeal inflammation
  with fever, throat pain, odynophagia, and tender anterior cervical
  lymphadenopathy. Untreated infection can spread contiguously or seed
  post-streptococcal immune sequelae, motivating throat-swab confirmation and
  prompt narrow-spectrum antibiotic treatment.
category: Infectious Disease
disease_term:
  preferred_term: streptococcal sore throat
  term:
    id: MONDO:0021783
    label: streptococcal sore throat
parents:
- Bacterial infection
synonyms:
- Group A Streptococcal Pharyngitis
- Group A beta-hemolytic Streptococcal Pharyngitis
- GABHS Pharyngitis
- Strep Throat
- Streptococcal Sore Throat
notes: >-
  Deep research was run with the openscientist provider. The report's
  reference-validation pass resolved all 43 PMIDs and found no off-topic
  references, but its term-validation pass flagged several real identifiers with
  wrong labels, including MONDO:0005295 misnamed as rheumatic heart disease,
  UBERON:0002007 misnamed as heart valve, and NCIT:C61785/NCIT:C287 misnamed as
  penicillin/amoxicillin; those suggestions were not used. The report also
  surfaced sequela literature for rheumatic heart disease, acute
  post-streptococcal glomerulonephritis, and PANDAS/Sydenham chorea, plus
  preclinical group A Streptococcus vaccine work; this entry consumes those
  leads only as complication context because the dedicated entity here is acute
  streptococcal sore throat, distinct from Scarlet_Fever,
  Rheumatic_Heart_Disease, and
  Pediatric_Autoimmune_Neuropsychiatric_Disorders_Associated_With_Streptococcal_Infections.
  SpeA is also epidemiologically linked to scarlet-fever outbreaks; this entry
  models SpeA only as a tonsillar superantigen, leaving the scarlatiniform
  rash syndrome to Scarlet_Fever.
infectious_agent:
- name: Streptococcus pyogenes
  infectious_agent_term:
    preferred_term: Streptococcus pyogenes
    term:
      id: NCBITaxon:1314
      label: Streptococcus pyogenes
  description: >-
    Streptococcus pyogenes, or group A Streptococcus, is a human-adapted
    beta-hemolytic coccus that colonizes the upper respiratory tract and can
    cause acute pharyngitis.
  evidence:
  - reference: PMID:40572286
    reference_title: "From Infection to Autoimmunity: S. pyogenes as a Model Pathogen."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Group A beta-hemolytic Streptococcus (GAS) is a Gram-positive,
      coccoid-shaped bacterium that tends to grow in chains; it is a
      non-spore-forming, facultatively anaerobic, catalase-negative, aerobic
      bacterium. It is known to cause a wide range of infections in children,
      ranging from mild upper respiratory tract infections, such as pharyngitis,
      to severe invasive disease.
    explanation: >-
      This review identifies group A Streptococcus as the bacterial agent that
      causes pharyngitis.
transmission:
- name: Close-contact and respiratory-droplet spread
  description: >-
    Group A Streptococcus spreads between humans through close or direct contact
    and especially through respiratory droplets, with the upper respiratory tract
    serving as a major reservoir.
  evidence:
  - reference: PMID:27312939
    reference_title: "Streptococcus pyogenes adhesion and colonization."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The main route of GAS transmission between humans is through close or
      direct physical contact, and particularly via respiratory droplets. The
      upper respiratory tract and skin are major reservoirs for GAS infections.
    explanation: >-
      This supports close-contact and droplet transmission from upper-airway
      reservoirs.
classifications:
  harrisons_chapter:
  - classification_value: INFECTIOUS_DISEASES
    evidence:
    - reference: PMID:40572286
      reference_title: "From Infection to Autoimmunity: S. pyogenes as a Model Pathogen."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        It is known to cause a wide range of infections in children, ranging
        from mild upper respiratory tract infections, such as pharyngitis, to
        severe invasive disease.
      explanation: >-
        Streptococcal pharyngitis is a bacterial upper respiratory tract
        infection, placing it in Harrison's Infectious Diseases Part.
pathophysiology:
- name: Streptococcal Pharyngeal Adhesion and Colonization
  role: trigger
  description: >-
    Streptococcus pyogenes uses surface adhesins and pili to attach to and
    colonize pharyngeal and tonsillar epithelial surfaces, establishing the
    mucosal infection that initiates group A streptococcal pharyngitis.
  locations:
  - preferred_term: pharynx
    term:
      id: UBERON:0006562
      label: pharynx
  - preferred_term: tonsil
    term:
      id: UBERON:0002372
      label: tonsil
  cell_types:
  - preferred_term: pharyngeal and tonsillar epithelial cell
    term:
      id: CL:0000066
      label: epithelial cell
  biological_processes:
  - preferred_term: adhesion of symbiont to host
    term:
      id: GO:0044406
      label: adhesion of symbiont to host
  - preferred_term: response to bacterium
    modifier: ABNORMAL
    term:
      id: GO:0009617
      label: response to bacterium
  downstream:
  - target: SpeA-Mediated Tonsillar Immune Dysregulation
    description: Toxigenic strains can express SpeA superantigen in the tonsillar niche.
  - target: Acute Pharyngotonsillar Inflammation
    description: Mucosal GAS colonization triggers the acute local inflammatory syndrome.
  evidence:
  - reference: PMID:27312939
    reference_title: "Streptococcus pyogenes adhesion and colonization."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The upper respiratory tract and skin are major reservoirs for GAS
      infections. The ability of GAS to establish an infection in the new host
      at these anatomical sites primarily results from two distinct
      physiological processes, namely bacterial adhesion and colonization.
    explanation: >-
      This supports epithelial adhesion and colonization as the initiating steps
      at GAS mucosal reservoirs.
  - reference: PMID:33623073
    reference_title: A multivalent T-antigen-based vaccine for Group A Streptococcus.
    supports: SUPPORT
    quote_role: BACKGROUND
    evidence_source: OTHER
    snippet: >-
      Pili of Group A Streptococcus (GAS) are surface-exposed structures
      involved in adhesion and colonisation of the host during infection. The
      major protein component of the GAS pilus is the T-antigen, which
      multimerises to form the pilus shaft.
    explanation: >-
      This supports GAS pili and T-antigen as surface adhesins that contribute
      to host colonization.
- name: SpeA-Mediated Tonsillar Immune Dysregulation
  role: amplifier
  description: >-
    Streptococcal pyrogenic exotoxin A and related superantigens can drive
    proliferation of human tonsillar T cells, alter T follicular helper-cell
    phenotype, and induce B-cell apoptosis with reduced immunoglobulin release,
    providing superantigen-producing organisms with a local survival advantage.
  locations:
  - preferred_term: tonsil
    term:
      id: UBERON:0002372
      label: tonsil
  cell_types:
  - preferred_term: tonsillar T cell
    term:
      id: CL:0000084
      label: T cell
  - preferred_term: tonsillar B cell
    term:
      id: CL:0000236
      label: B cell
  biological_processes:
  - preferred_term: T cell activation
    modifier: INCREASED
    term:
      id: GO:0042110
      label: T cell activation
  - preferred_term: B-cell apoptotic process
    modifier: INCREASED
    term:
      id: GO:0006915
      label: apoptotic process
  downstream:
  - target: Acute Pharyngotonsillar Inflammation
    description: SpeA-stimulated tonsil T cells release proinflammatory cytokines.
  evidence:
  - reference: PMID:30815853
    reference_title: "Streptococcal superantigen-induced expansion of human tonsil T cells leads to altered T follicular helper cell phenotype, B cell death and reduced immunoglobulin release."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Tonsil T cells proliferated in response to SpeA and demonstrated typical
      release of proinflammatory cytokines. When cultured in the absence of
      superantigen, tonsil preparations released large quantities of
      immunoglobulin over 7 days. In contrast, marked B cell apoptosis and
      abrogation of total immunoglobulin (Ig)A, IgM, and IgG production occurred
      in the presence of SpeA and other superantigens.
    explanation: >-
      This human tonsil-cell experiment directly supports SpeA-driven T-cell
      activation and B-cell death in the tissue affected by GAS
      tonsillopharyngitis.
- name: Acute Pharyngotonsillar Inflammation
  role: consequence
  description: >-
    Infection-induced inflammation of the pharynx, tonsils, uvula, and draining
    anterior cervical lymph nodes accounts for the characteristic abrupt fever,
    sore throat, odynophagia, pharyngitis, and tender anterior cervical
    lymphadenopathy of streptococcal pharyngitis.
  locations:
  - preferred_term: pharynx
    term:
      id: UBERON:0006562
      label: pharynx
  - preferred_term: tonsil
    term:
      id: UBERON:0002372
      label: tonsil
  biological_processes:
  - preferred_term: inflammatory response
    modifier: INCREASED
    term:
      id: GO:0006954
      label: inflammatory response
  downstream:
  - target: Pharyngitis
    description: Pharyngeal inflammation produces the defining pharyngitis.
  - target: Enlarged tonsils
    description: Tonsillar inflammation produces tonsillar enlargement.
  - target: Tonsillar exudate
    description: Pharyngotonsillar inflammation can produce tonsillar exudate.
  - target: Pharyngalgia
    description: Local inflammation produces intense throat pain.
  - target: Odynophagia
    description: Throat inflammation produces pain on swallowing.
  - target: Fever
    description: GAS pharyngitis produces abrupt systemic fever.
  - target: Cervical lymphadenopathy
    description: Regional immune activation enlarges tender anterior cervical lymph nodes.
  - target: Contiguous Suppurative Spread
    description: Local spread can produce otitis media, sinusitis, and other suppurative complications.
  - target: Post-Streptococcal Immune Sequelae
    description: A subset of infections can trigger autoimmune sequelae after the acute pharyngeal infection.
  evidence:
  - reference: PMID:37493159
    reference_title: "Group A β-hemolytic Streptococcal Pharyngitis: An Updated Review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Children with GABHS pharyngitis typically present with an abrupt onset of
      fever, intense pain in the throat, pain on swallowing, an inflamed
      pharynx, enlarged and erythematous tonsils, a red and swollen uvula,
      enlarged tender anterior cervical lymph nodes.
    explanation: >-
      This clinical review links acute GABHS pharyngitis to the local
      pharyngotonsillar inflammatory findings and systemic fever.
- name: Contiguous Suppurative Spread
  role: complication
  description: >-
    Local extension from group A streptococcal pharyngitis can produce
    suppurative complications, including otitis media, sinusitis, mastoiditis,
    and peritonsillar or retropharyngeal abscess.
  biological_processes:
  - preferred_term: inflammatory response
    modifier: INCREASED
    term:
      id: GO:0006954
      label: inflammatory response
  downstream:
  - target: Otitis media
    description: Contiguous spread can produce acute middle-ear infection.
  - target: Sinusitis
    description: Contiguous spread can produce acute sinusitis.
  - target: Peritonsillar abscess
    description: Local suppurative spread can produce quinsy.
  evidence:
  - reference: PMID:23067784
    reference_title: "Rapidly progressing subperiosteal orbital abscess: an unexpected complication of a group-A streptococcal pharyngitis in a healthy young patient."
    supports: SUPPORT
    quote_role: BACKGROUND
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Complications associated to group-A streptococcal pharyingitis include
      non-suppurative complications such as acute rheumatic fever and
      glomerulonephritis and suppurative complications such as peritonsillar or
      retropharyngeal abscess, sinusitis, mastoiditis, otitis media, meningitis,
      brain abscess, or thrombosis of the intracranial venous sinuses.
    explanation: >-
      This case report and literature review supports otitis media and sinusitis
      as recognized suppurative complications of GAS pharyngitis.
- name: Post-Streptococcal Immune Sequelae
  role: complication
  description: >-
    Group A Streptococcus can trigger post-infectious immune complications after
    pharyngitis, including acute rheumatic fever, acute post-streptococcal
    glomerulonephritis, and rheumatic heart disease.
  biological_processes:
  - preferred_term: immune response
    modifier: ABNORMAL
    term:
      id: GO:0006955
      label: immune response
  evidence:
  - reference: PMID:40572286
    reference_title: "From Infection to Autoimmunity: S. pyogenes as a Model Pathogen."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      GAS also notably triggers post-infectious immune sequelae, including
      acute poststreptococcal glomerulonephritis (APSGN), acute rheumatic fever
      (ARF), and rheumatic heart disease (RHD), which are major health burdens,
      especially in low-income countries.
    explanation: >-
      This review supports post-streptococcal immune disease as a downstream
      branch of GAS infection without re-curating those distinct sequelae here.
- name: Streptococcal Peptidoglycan Cross-Linking
  role: therapeutic_vulnerability
  conforms_to: "bacterial_cell_wall_synthesis_inhibition#Peptidoglycan Cross-Linking by Penicillin-Binding Proteins"
  description: >-
    Streptococcus pyogenes depends on penicillin-binding-protein
    transpeptidation to cross-link its peptidoglycan cell wall; beta-lactam
    antibiotics inhibit this reaction and group A Streptococcus remains
    universally susceptible to penicillin.
  biological_processes:
  - preferred_term: Peptidoglycan-Based Cell Wall Biogenesis
    term:
      id: GO:0009273
      label: peptidoglycan-based cell wall biogenesis
  evidence:
  - reference: PMID:39259691
    reference_title: "Chains of misery: surging invasive group A streptococcal disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      GAS remains universally susceptible to penicillin but there are increasing
      reports of macrolide and lincosamide resistance, particularly in invasive
      isolates, with uncertain clinical consequences.
    explanation: >-
      Universal penicillin susceptibility supports cell-wall beta-lactams as an
      active therapeutic vulnerability in GAS.
- name: Streptococcal Ribosomal Translation
  role: therapeutic_vulnerability
  conforms_to: "bacterial_protein_synthesis_inhibition#Bacterial mRNA Translation by the Ribosome"
  description: >-
    Streptococcus pyogenes depends on 70S-ribosome translation. Clindamycin and
    macrolides target the 50S ribosome and are treatment alternatives for
    immediate-type penicillin hypersensitivity.
  biological_processes:
  - preferred_term: Translation
    term:
      id: GO:0006412
      label: translation
  evidence:
  - reference: PMID:12860123
    reference_title: "The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      The macrolide-lincosamide-streptogramin B class (MLS) of antibiotics
      contains structurally different but functionally similar drugs, that all
      bind to the 50S ribosomal subunit. It has been suggested that these
      compounds block the path by which nascent peptides exit the ribosome. We
      have studied the mechanisms of action of four macrolides (erythromycin,
      josamycin, spiramycin and telithromycin), one lincosamide (clindamycin)
      and one streptogramin B (pristinamycin IA). All these MLS drugs cause
      dissociation of peptidyl-tRNA from the ribosome.
    explanation: >-
      This cell-free ribosome study supports 50S binding and peptide-exit
      blockade by the macrolide and lincosamide drug classes represented by this
      node.
phenotypes:
- category: Head and neck
  name: Pharyngitis
  description: Acute pharyngeal inflammation is the defining manifestation.
  phenotype_term:
    preferred_term: Pharyngitis
    term:
      id: HP:0025439
      label: Pharyngitis
  evidence:
  - reference: PMID:37493159
    reference_title: "Group A β-hemolytic Streptococcal Pharyngitis: An Updated Review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Children with GABHS pharyngitis typically present with an abrupt onset of
      fever, intense pain in the throat, pain on swallowing, an inflamed
      pharynx, enlarged and erythematous tonsils, a red and swollen uvula,
      enlarged tender anterior cervical lymph nodes.
    explanation: >-
      This supports pharyngeal inflammation as a presenting manifestation of
      GABHS pharyngitis.
- category: Head and neck
  name: Pharyngalgia
  description: Severe sore throat is a typical symptom.
  phenotype_term:
    preferred_term: Sore throat
    term:
      id: HP:0033050
      label: Pharyngalgia
  evidence:
  - reference: PMID:37493159
    reference_title: "Group A β-hemolytic Streptococcal Pharyngitis: An Updated Review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Children with GABHS pharyngitis typically present with an abrupt onset of
      fever, intense pain in the throat, pain on swallowing, an inflamed
      pharynx, enlarged and erythematous tonsils, a red and swollen uvula,
      enlarged tender anterior cervical lymph nodes.
    explanation: >-
      This supports intense throat pain as a symptom of GABHS pharyngitis; HPO
      lists Sore throat as an exact synonym of Pharyngalgia.
- category: Head and neck
  name: Enlarged tonsils
  description: Tonsillar enlargement is a typical local sign.
  phenotype_term:
    preferred_term: Enlarged tonsils
    term:
      id: HP:0030812
      label: Enlarged tonsils
  evidence:
  - reference: PMID:37493159
    reference_title: "Group A β-hemolytic Streptococcal Pharyngitis: An Updated Review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Children with GABHS pharyngitis typically present with an abrupt onset of
      fever, intense pain in the throat, pain on swallowing, an inflamed
      pharynx, enlarged and erythematous tonsils, a red and swollen uvula,
      enlarged tender anterior cervical lymph nodes.
    explanation: >-
      This supports enlarged tonsils as a presenting local inflammatory sign.
- category: Head and neck
  name: Tonsillar exudate
  description: Tonsillar coating or exudate is enriched in GAS pharyngotonsillitis.
  phenotype_term:
    preferred_term: Tonsillar exudate
    term:
      id: HP:0034035
      label: Pharyngeal exudate
  notes: >-
    HPO has HP:0034035 for pharyngeal exudate but no tonsil-specific exudate
    term: `runoak -i ols:hp search "l~tonsillar"` returned no candidate, and
    `runoak -i ols:hp search "l~exudate"` returned HP:0034035 as the only
    upper-airway exudate term.
  evidence:
  - reference: PMID:34535115
    reference_title: "The aetiology of pharyngotonsillitis in primary health care: a prospective observational study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Both cough and coryza were more common in patients with only viruses
      (67%) than in patients with only bacteria (21%) (p < 0.001), whereas
      tonsillar coating was more common in patients with only bacteria (53%)
      than in patients with only viruses (29%) (p = 0.006).
    explanation: >-
      This prospective pharyngotonsillitis study supports tonsillar coating as
      a bacterial-enriched local finding.
- category: Head and neck
  name: Odynophagia
  description: Pain on swallowing can accompany acute GABHS pharyngitis.
  phenotype_term:
    preferred_term: Odynophagia
    term:
      id: HP:0032043
      label: Odynophagia
  evidence:
  - reference: PMID:37493159
    reference_title: "Group A β-hemolytic Streptococcal Pharyngitis: An Updated Review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Children with GABHS pharyngitis typically present with an abrupt onset of
      fever, intense pain in the throat, pain on swallowing, an inflamed
      pharynx, enlarged and erythematous tonsils, a red and swollen uvula,
      enlarged tender anterior cervical lymph nodes.
    explanation: This supports pain on swallowing in the clinical presentation.
- category: Constitutional
  name: Fever
  description: Fever is a common systemic manifestation.
  phenotype_term:
    preferred_term: Fever
    term:
      id: HP:0001945
      label: Fever
  evidence:
  - reference: PMID:37493159
    reference_title: "Group A β-hemolytic Streptococcal Pharyngitis: An Updated Review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Children with GABHS pharyngitis typically present with an abrupt onset of
      fever, intense pain in the throat, pain on swallowing, an inflamed
      pharynx, enlarged and erythematous tonsils, a red and swollen uvula,
      enlarged tender anterior cervical lymph nodes.
    explanation: This supports abrupt fever as a presenting manifestation.
- category: Head and neck
  name: Cervical lymphadenopathy
  description: Tender anterior cervical lymph-node enlargement is typical.
  phenotype_term:
    preferred_term: Cervical lymphadenopathy
    term:
      id: HP:0025289
      label: Cervical lymphadenopathy
  evidence:
  - reference: PMID:37493159
    reference_title: "Group A β-hemolytic Streptococcal Pharyngitis: An Updated Review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Children with GABHS pharyngitis typically present with an abrupt onset of
      fever, intense pain in the throat, pain on swallowing, an inflamed
      pharynx, enlarged and erythematous tonsils, a red and swollen uvula,
      enlarged tender anterior cervical lymph nodes.
    explanation: This supports tender anterior cervical lymphadenopathy.
- category: Head and neck
  name: Otitis media
  description: Acute otitis media is a recognized suppurative complication.
  phenotype_term:
    preferred_term: Otitis media
    term:
      id: HP:0000388
      label: Otitis media
  evidence:
  - reference: PMID:17054126
    reference_title: "Antibiotics for sore throat."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Suppurative complications: Antibiotics reduced the incidence of acute
      otitis media (RR 0.30; 95% CI 0.15 to 0.58); of acute sinusitis (RR 0.48;
      95% CI 0.08 to 2.76); and of quinsy (peritonsillar abscess) compared to
      those taking placebo (RR 0.15; 95% CI 0.05 to 0.47).
    explanation: >-
      This Cochrane review supports otitis media as a suppurative complication
      tracked in sore-throat antibiotic trials.
- category: Head and neck
  name: Sinusitis
  description: Acute sinusitis is a recognized suppurative complication.
  phenotype_term:
    preferred_term: Sinusitis
    term:
      id: HP:0000246
      label: Sinusitis
  evidence:
  - reference: PMID:17054126
    reference_title: "Antibiotics for sore throat."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Suppurative complications: Antibiotics reduced the incidence of acute
      otitis media (RR 0.30; 95% CI 0.15 to 0.58); of acute sinusitis (RR 0.48;
      95% CI 0.08 to 2.76); and of quinsy (peritonsillar abscess) compared to
      those taking placebo (RR 0.15; 95% CI 0.05 to 0.47).
    explanation: >-
      This Cochrane review supports acute sinusitis as a suppurative
      complication tracked in sore-throat antibiotic trials.
- category: Head and neck
  name: Peritonsillar abscess
  description: Peritonsillar abscess, or quinsy, is a suppurative complication.
  notes: >-
    No HPO term is bound because `runoak -i ols:hp search
    "l~peritonsillar"` and `runoak -i ols:hp search "l~quinsy"` returned no
    candidate terms.
  evidence:
  - reference: PMID:17054126
    reference_title: Antibiotics for sore throat.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Suppurative complications: Antibiotics reduced the incidence of acute
      otitis media (RR 0.30; 95% CI 0.15 to 0.58); of acute sinusitis (RR 0.48;
      95% CI 0.08 to 2.76); and of quinsy (peritonsillar abscess) compared to
      those taking placebo (RR 0.15; 95% CI 0.05 to 0.47).
    explanation: >-
      This Cochrane review supports quinsy as a suppurative complication
      tracked in sore-throat antibiotic trials.
diagnosis:
- name: Throat swab microbiologic testing
  description: >-
    Suspected group A streptococcal pharyngitis is confirmed with throat-swab
    microbiologic testing, such as culture, rapid antigen detection testing, or
    molecular point-of-care testing.
  diagnosis_term:
    preferred_term: diagnostic procedure
    term:
      id: NCIT:C18020
      label: Diagnostic Procedure
  results: Detection of group A Streptococcus from a throat swab supports the diagnosis in a compatible clinical syndrome.
  notes: >-
    A positive swab alone does not establish active disease when it reflects
    asymptomatic carriage, so testing and treatment are framed around a
    compatible clinical syndrome.
  evidence:
  - reference: PMID:37493159
    reference_title: "Group A β-hemolytic Streptococcal Pharyngitis: An Updated Review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Patients suspected of having GABHS pharyngitis should be confirmed by
      microbiologic testing (e.g., culture, rapid antigen detection test,
      molecular point-of-care test) of a throat swab specimen prior to the
      initiation of antimicrobial therapy.
    explanation: >-
      This supports throat-swab microbiologic confirmation before antibiotic
      therapy in suspected GABHS pharyngitis.
  - reference: PMID:22691611
    reference_title: "Management of acute pharyngitis in children: summary of the Italian National Institute of Health guidelines."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Because the carrier state is not associated with increased risk of
      suppurative complications and risk of GABHS transmission to contacts is
      minimal, the carrier state should never be investigated and treated.
    explanation: >-
      This guideline supports interpreting a positive GABHS test in clinical
      context rather than investigating asymptomatic carriage as acute disease.
- name: Clinical-score triage
  description: >-
    Centor-style clinical scores can use features such as cough absence and
    tonsillar coating to guide microbiologic testing, but score-only diagnosis
    is insufficient in children with sore throat.
  diagnosis_term:
    preferred_term: diagnostic procedure
    term:
      id: NCIT:C18020
      label: Diagnostic Procedure
  results: Centor score alone is not adequate to diagnose or exclude pediatric GAS pharyngitis.
  evidence:
  - reference: PMID:39528865
    reference_title: "Centor scores associated poorly with rapid antigen test findings in children with sore throat."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The Centor score alone does not seem to be of any utility in guiding the
      diagnosis of suspected streptococcal pharyngitis. Microbiological testing
      remains necessary for accurate diagnosis and CRP should not be used to
      differentiate viral and bacterial pharyngitis cases.
    explanation: >-
      This pediatric study supports the limitation of clinical-score-only
      diagnosis and the need for microbiologic testing.
  - reference: PMID:34535115
    reference_title: "The aetiology of pharyngotonsillitis in primary health care: a prospective observational study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Tonsillar coating (adjusted OR 6.0; 95% CI 2.5-14) and a lack of cough
      (adjusted OR 3.5; 95% CI 1.5-8.0) were significantly associated with
      Streptococcus pyogenes (group A streptococci; GAS) and with any bacterial
      finding.
    explanation: >-
      This supports tonsillar coating and absence of cough as clinical features
      that raise the probability of GAS pharyngotonsillitis.
  - reference: PMID:38182052
    reference_title: Systematic review and meta-analysis of the accuracy of McIsaac and Centor score in patients presenting to secondary care with pharyngitis.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Centor and McIsaac scores are clinical prediction rules for diagnosing
      group A streptococcus (GAS) infection in patients with pharyngitis. Their
      recommended thresholds vary between guidelines.
    explanation: >-
      This meta-analysis identifies Centor and McIsaac as GAS pharyngitis
      triage scores with guideline-dependent thresholds.
treatments:
- name: Beta-lactam antibiotic therapy
  description: >-
    Penicillin or amoxicillin treats confirmed group A streptococcal pharyngitis
    by targeting streptococcal peptidoglycan cross-linking, while effective
    microbiologic treatment also provides primary prevention of acute rheumatic
    fever.
  treatment_term:
    preferred_term: antimicrobial agent therapy
    term:
      id: NCIT:C15620
      label: Antibiotic Therapy
    therapeutic_agent:
    - preferred_term: penicillin
      term:
        id: CHEBI:17334
        label: penicillin
    - preferred_term: amoxicillin
      term:
        id: CHEBI:2676
        label: amoxicillin
    - preferred_term: benzathine penicillin G
      term:
        id: CHEBI:756117
        label: penicillin g benzathine
  therapeutic_modality: SMALL_MOLECULE
  target_phenotypes:
  - preferred_term: Pharyngitis
    term:
      id: HP:0025439
      label: Pharyngitis
  - preferred_term: Fever
    term:
      id: HP:0001945
      label: Fever
  - preferred_term: Sore throat
    term:
      id: HP:0033050
      label: Pharyngalgia
  target_mechanisms:
  - target: Streptococcal Peptidoglycan Cross-Linking
    description: >-
      Beta-lactams inhibit the penicillin-binding-protein transpeptidation
      needed for peptidoglycan cross-linking in GAS.
  - target: Post-Streptococcal Immune Sequelae
    description: >-
      Prompt antibiotic treatment of streptococcal pharyngitis prevents many
      acute rheumatic fever episodes.
  evidence:
  - reference: PMID:37493159
    reference_title: "Group A β-hemolytic Streptococcal Pharyngitis: An Updated Review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Antimicrobial therapy should be initiated without delay once the diagnosis
      is confirmed. Oral penicillin V and amoxicillin remain the drugs of
      choice.
    explanation: >-
      This supports penicillin and amoxicillin as first-line therapy for
      confirmed GABHS pharyngitis.
  - reference: PMID:22691611
    reference_title: "Management of acute pharyngitis in children: summary of the Italian National Institute of Health guidelines."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Antibiotic therapy is recommended in microbiologically documented GABHS
      pharyngitis. Because penicillin V is not available in Italy, amoxicillin
      (50 mg/kg/d in 2-3 doses orally) for 10 days is the first choice of
      treatment. In noncompliant cases, benzathine penicillin may be
      administered.
    explanation: >-
      This national-guideline summary supports amoxicillin treatment for
      documented GABHS pharyngitis and intramuscular benzathine penicillin for
      patients who may not complete oral therapy.
  - reference: PMID:41956705
    reference_title: Implementation and evaluation of a pragmatic community streptococcal treatment programme to improve rheumatic heart disease primary prevention in Uganda.
    supports: SUPPORT
    quote_role: BACKGROUND
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Detection and treatment of streptococcal pharyngitis in children reduces
      acute rheumatic fever by 70-80%.
    explanation: >-
      This supports antibiotic treatment of streptococcal pharyngitis as
      primary prevention for acute rheumatic fever.
  - reference: PMID:37965935
    reference_title: "Different antibiotic treatments for group A streptococcal pharyngitis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Antibiotics provide only modest benefit in treating sore throat, although
      their effectiveness increases in people with positive throat swabs for
      group A beta-haemolytic streptococci (GABHS).
    explanation: >-
      This Cochrane review supports antibiotic benefit being most relevant after
      a positive GAS throat swab.
- name: Antipyretic and analgesic symptom relief
  description: >-
    Ibuprofen or paracetamol can be used to relieve fever and painful sore
    throat discomfort during acute pharyngitis.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: ibuprofen
      term:
        id: CHEBI:5855
        label: ibuprofen
    - preferred_term: paracetamol
      term:
        id: CHEBI:46195
        label: paracetamol
  therapeutic_modality: SMALL_MOLECULE
  target_phenotypes:
  - preferred_term: Fever
    term:
      id: HP:0001945
      label: Fever
  - preferred_term: Sore throat
    term:
      id: HP:0033050
      label: Pharyngalgia
  evidence:
  - reference: PMID:22691611
    reference_title: "Management of acute pharyngitis in children: summary of the Italian National Institute of Health guidelines."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Ibuprofen or paracetamol is recommended for relief of pain or fever
      associated with discomfort.
    explanation: >-
      This guideline supports NSAID or paracetamol symptom relief for painful or
      febrile acute pharyngitis.
- name: Alternative antibiotics for penicillin allergy
  description: >-
    Cephalosporins can be used for non-anaphylactic penicillin allergy, while
    clindamycin and macrolides are alternatives for immediate-type penicillin
    hypersensitivity.
  treatment_term:
    preferred_term: antimicrobial agent therapy
    term:
      id: NCIT:C15620
      label: Antibiotic Therapy
    therapeutic_agent:
    - preferred_term: cephalosporin
      term:
        id: CHEBI:23066
        label: cephalosporin
    - preferred_term: clindamycin
      term:
        id: CHEBI:3745
        label: clindamycin
    - preferred_term: azithromycin
      term:
        id: CHEBI:2955
        label: azithromycin
    - preferred_term: clarithromycin
      term:
        id: CHEBI:3732
        label: clarithromycin
  therapeutic_modality: SMALL_MOLECULE
  target_phenotypes:
  - preferred_term: Pharyngitis
    term:
      id: HP:0025439
      label: Pharyngitis
  - preferred_term: Sore throat
    term:
      id: HP:0033050
      label: Pharyngalgia
  target_mechanisms:
  - target: Streptococcal Peptidoglycan Cross-Linking
    description: Cephalosporins retain the beta-lactam PBP target.
  - target: Streptococcal Ribosomal Translation
    description: Clindamycin and macrolides target the bacterial ribosome.
  evidence:
  - reference: PMID:37493159
    reference_title: "Group A β-hemolytic Streptococcal Pharyngitis: An Updated Review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      For patients who have a non-anaphylactic allergy to penicillin, oral
      cephalosporin is an acceptable alternative. For patients with a history of
      immediate, anaphylactic-type hypersensitivity to penicillin, oral
      clindamycin, clarithromycin, and azithromycin are acceptable alternatives.
    explanation: >-
      This supports cephalosporin, clindamycin, azithromycin, and
      clarithromycin alternatives for patients with penicillin allergy.
📚

References & Deep Research

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (2)

Record notes

Deep research was run with the openscientist provider. The report's reference-validation pass resolved all 43 PMIDs and found no off-topic references, but its term-validation pass flagged several real identifiers with wrong labels, including MONDO:0005295 misnamed as rheumatic heart disease, UBERON:0002007 misnamed as heart valve, and NCIT:C61785/NCIT:C287 misnamed as penicillin/amoxicillin; those suggestions were not used. The report also surfaced sequela literature for rheumatic heart disease, acute post-streptococcal glomerulonephritis, and PANDAS/Sydenham chorea, plus preclinical group A Streptococcus vaccine work; this entry consumes those leads only as complication context because the dedicated entity here is acute streptococcal sore throat, distinct from Scarlet_Fever, Rheumatic_Heart_Disease, and Pediatric_Autoimmune_Neuropsychiatric_Disorders_Associated_With_Streptococcal_Infections. SpeA is also epidemiologically linked to scarlet-fever outbreaks; this entry models SpeA only as a tonsillar superantigen, leaving the scarlatiniform rash syndrome to Scarlet_Fever.

Create: Streptococcal_Pharyngitis · 2026-09-27T07:07:41Z · View source

Created a new MONDO:0021783 streptococcal sore throat entry from an OpenScientist deep-research report, after discarding mislabelled report term suggestions for rheumatic heart disease, heart valve, penicillin, and amoxicillin. Curated GAS pharyngeal adhesion and colonization, SpeA-mediated tonsillar immune dysregulation, acute pharyngotonsillar inflammation, suppurative and post-streptococcal complication nodes, beta-lactam and ribosomal therapeutic vulnerabilities, eight wired phenotypes, throat-swab and clinical-score diagnostic records, and first-line plus penicillin-allergy antibiotic treatments. Validated with just validate, count-verified-snippets, check_causal_targets, check_duplicate_yaml_keys, and list-disconnected-phenotypes.

OpenScientist ▸
Streptococcal Pharyngitis (MONDO:0021783): A Comprehensive Disease Characteristics Report
openscientist-autonomous 43 citations 2026-09-26T23:57:55.567711

Streptococcal Pharyngitis (MONDO:0021783): A Comprehensive Disease Characteristics Report

Category: Infectious Disease · Evidence base: 55 papers reviewed, 12 confirmed findings

Summary

Streptococcal pharyngitis is an acute, usually self-limited infectious tonsillopharyngitis caused by Group A Streptococcus (Streptococcus pyogenes, GAS). The organism — a Gram-positive, catalase-negative, β-hemolytic coccus growing in chains — colonizes the pharyngeal epithelium of the upper respiratory tract, which is a major human reservoir. Adhesion and colonization, mediated by virulence factors including M protein, streptokinase, and pili (T-antigen), are the initiating mechanistic steps. The infection produces a characteristic clinical picture of abrupt fever, severe sore throat, odynophagia, tonsillar exudate, palatal petechiae, a swollen red uvula, and tender anterior cervical lymphadenopathy, typically in children aged 5–15 years.

The disproportionate clinical importance of this common illness derives not from the acute pharyngitis itself — which resolves in most patients within a week — but from its complications. These fall into two branches: (1) suppurative complications from local/contiguous spread (peritonsillar and retropharyngeal abscess, otitis media, sinusitis, mastoiditis, and rarely intracranial extension); and (2) non-suppurative autoimmune sequelae driven by molecular mimicry between streptococcal antigens (particularly M protein) and human tissue — acute rheumatic fever (ARF), rheumatic heart disease (RHD), acute post-streptococcal glomerulonephritis (APSGN), and neuropsychiatric sequelae (Sydenham chorea; the proposed PANDAS entity). Only a small fraction of infections progress to these sequelae, and this progression is gated by host genetics, chiefly HLA class II alleles.

Clinically, diagnosis requires microbiological confirmation (rapid antigen detection test [RADT], throat culture, or molecular point-of-care test) rather than clinical scoring alone, because GAS pharyngitis is phenotypically indistinguishable from viral and non-group-A streptococcal causes. Treatment with penicillin or amoxicillin — to which GAS remains universally susceptible — provides modest symptomatic benefit but importantly reduces suppurative complications and lowers ARF incidence by 70–80%. The autoimmune sequelae are diagnosed by dedicated frameworks (the 2015 revised Jones criteria for ARF, with Doppler echocardiography), and secondary benzathine penicillin G prophylaxis prevents progression of latent RHD (GOAL randomized controlled trial). RHD affects more than 40.5 million people worldwide and causes ~306,000 deaths annually, making primary and secondary prevention of streptococcal pharyngitis a global public-health priority.

Disease Information (Section 1)

Streptococcal pharyngitis (also "strep throat," GAS/GABHS pharyngitis, streptococcal tonsillopharyngitis, streptococcal sore throat) is an acute bacterial infection of the pharynx and tonsils caused by Streptococcus pyogenes. Key identifiers:

Resource Identifier
Mondo MONDO:0021783
ICD-10 J02.0 (streptococcal pharyngitis); J03.00 (acute streptococcal tonsillitis)
ICD-11 CA02.0
MeSH Pharyngitis (D010612); Streptococcus pyogenes (D013297); Streptococcal Infections (D013290)
NCBI Taxonomy Streptococcus pyogenes, txid1314
SNOMED CT 43878008 (streptococcal sore throat)

The information for this disease is derived from aggregated disease-level resources — clinical guidelines, Cochrane systematic reviews, epidemiological studies, and mechanistic literature — rather than individual patient EHR records (though some cited cohorts, e.g., PMID 34805428, are EHR-based). OMIM and Orphanet do not assign a primary entry to streptococcal pharyngitis itself (it is not a Mendelian disorder), though related host-susceptibility phenotypes for rheumatic fever/RHD appear in the genetics literature.

Key Findings

F001 — Streptococcus pyogenes (Group A Streptococcus) is the causal agent

GAS is a Gram-positive, catalase-negative, β-hemolytic coccus that grows in chains and colonizes the upper respiratory tract, which serves as a major reservoir. Bacterial adhesion and colonization of the pharyngeal epithelium are the initiating steps of infection, mediated by virulence factors including M protein and streptokinase.

"The upper respiratory tract and skin are major reservoirs for GAS infections. The ability of GAS to establish an infection in the new host at these anatomical sites primarily results from two distinct physiological processes, namely bacterial adhesion and colonization." — PMID: 27312939

"It is known to cause a wide range of infections in children, ranging from mild upper respiratory tract infections, such as pharyngitis, to severe invasive disease." — PMID: 40572286

Ontology suggestions: infectious agent NCBITaxon:1314 (S. pyogenes); GO:0007155 (cell adhesion); UBERON:0006562 (pharynx); CL:0000066 (epithelial cell).

F002 — Post-streptococcal autoimmune sequelae (ARF, RHD, APSGN) arise via molecular mimicry

Acute rheumatic fever is an autoimmune disorder that follows GAS pharyngitis or impetigo in children and adolescents and may evolve into rheumatic heart disease with persistent valve damage. GAS triggers post-infectious sequelae — APSGN, ARF, and RHD — attributed largely to molecular mimicry between streptococcal antigens (e.g., M protein) and human tissue proteins. Critically, detection and treatment of streptococcal pharyngitis reduces ARF incidence by 70–80%, confirming the causal link.

"Acute rheumatic fever (ARF) is an autoimmune disorder resulting from Group A Streptococcus (GAS) pharyngitis or impetigo in children and adolescents, which may evolve to rheumatic heart disease (RHD) with persistent cardiac valve damage." — PMID: 40484016

"GAS also notably triggers post-infectious immune sequelae, including acute poststreptococcal glomerulonephritis (APSGN), acute rheumatic fever (ARF), and rheumatic heart disease (RHD), which are major health burdens, especially in low-income countries." — PMID: 40572286

"Detection and treatment of streptococcal pharyngitis in children reduces acute rheumatic fever by 70-80%." — PMID: 41956705

Ontology suggestions: GO:0002250 (adaptive immune response); GO:0042110 (T cell activation); MONDO:0005295 (rheumatic heart disease); UBERON:0002007 (heart valve).

F003 — Diagnosis requires microbiological confirmation; clinical scores are insufficient alone

Children with GABHS pharyngitis typically present with abrupt fever, intense throat pain, odynophagia, an inflamed pharynx, enlarged erythematous tonsils, a red swollen uvula, and tender anterior cervical lymphadenopathy. Because these features overlap with viral causes, suspected cases should be confirmed by microbiological testing (culture, RADT, or molecular point-of-care test) before starting antibiotics. Clinical scores perform poorly: in a pediatric cohort, a Centor score ≥3 had only 22.3% sensitivity and 79.0% specificity for RADT positivity, and 17.1% of RADT-negative patients had positive throat cultures.

"Children with GABHS pharyngitis typically present with an abrupt onset of fever, intense pain in the throat, pain on swallowing, an inflamed pharynx, enlarged and erythematous tonsils, a red and swollen uvula, enlarged tender anterior cervical lymph nodes." — PMID: 37493159

"Patients suspected of having GABHS pharyngitis should be confirmed by microbiologic testing (e.g., culture, rapid antigen detection test, molecular point-of-care test) of a throat swab specimen prior to the initiation of antimicrobial therapy." — PMID: 37493159

"The Centor score alone does not seem to be of any utility in guiding the diagnosis of suspected streptococcal pharyngitis." — PMID: 39528865

Supporting this, a systematic review and meta-analysis of McIsaac and Centor scores concluded both are "equally ineffective at triaging patients who need antibiotics" (PMID: 38182052). Cough and coryza are useful to rule out GAS; adding RADT to a Centor 3–4 raises positive predictive value to ~93% (PMID: 34535115). In college students, GAS and non-group-A streptococcal pharyngitis were clinically indistinguishable (PMID: 34805428).

Ontology / lab-test suggestions: HP:0025439 (pharyngitis); LOINC 626-2 (throat culture); LOINC 60489-2 (S. pyogenes rapid Ag).

F004 — GAS remains universally penicillin-susceptible; antibiotics give modest symptomatic benefit but prevent complications

GAS remains universally susceptible to penicillin, though macrolide and lincosamide resistance is increasing among invasive isolates, with uncertain clinical consequences. Antibiotics provide only modest benefit for sore-throat symptoms, but effectiveness increases in patients with GABHS-positive swabs.

"GAS remains universally susceptible to penicillin but there are increasing reports of macrolide and lincosamide resistance, particularly in invasive isolates, with uncertain clinical consequences." — PMID: 39259691

"Antibiotics provide only modest benefit in treating sore throat, although their effectiveness increases in people with positive throat swabs for group A beta-haemolytic streptococci (GABHS)." — PMID: 37965935 (Cochrane)

The Cochrane comparative-antibiotics review (19 trials, 5,839 participants) found no clinically relevant differences between cephalosporins/macrolides and penicillin for symptom resolution; given low cost and absence of resistance, penicillin remains first-line (PMID: 33728634). Where penicillin V is unavailable, amoxicillin 50 mg/kg/day for 10 days is first choice, with macrolides reserved for type-I penicillin allergy (PMID: 22691611).

Ontology suggestions (NCIT/CHEBI): NCIT:C61785 (Penicillin); NCIT:C287 (Amoxicillin); CHEBI:17334 (penicillin); CHEBI:2676 (amoxicillin).

F005 — Host HLA class II alleles modulate susceptibility to post-streptococcal rheumatic fever/RHD

Only a small fraction of GAS pharyngitis episodes progress to rheumatic carditis, implicating host genetics. A meta-analysis (13 studies; 1,065 patients / 1,691 controls) identified HLA-DRB1*07 as a susceptibility allele (OR ≈ 1.68) and HLA-DRB1*15 as protective. GWAS implicate the HLA-DQA1–HLA-DQB1 region and the immunoglobulin heavy-chain locus (IGHV4-61) on chromosome 14. Twin studies show much higher RF concordance in monozygotic (19%) than dizygotic (2.5%) twins. TNFA-308 and mannose-binding lectin (MBL) variants are also associated.

"The results of the meta-analysis suggest that the differential presentation of autoimmune peptides by HLA-DRB1*07 (susceptible) and HLA-DRB1*15 (protective) alleles with different affinities may play a crucial role in the pathogenesis of RF/RHD." — PMID: 32967480

"Early findings implicate not only HLA, particularly the HLA-DQA1 to HLA-DQB1 region, but also the immunoglobulin heavy chain locus, including the IGHV4-61 gene segment, on chromosome 14." — PMID: 31519994

"the high concordance rate for RF in monozygotic twins (19%) compared to dizygotic twins (2.5%), and the high familial incidence of RF suggest the involvement of host genetic factors in susceptibility to RF" — PMID: 37406855

An independent HLA study found HLA-DRB1*13, DRB5*, and DRB3* to be protective against rheumatic valve damage (PMID: 16426242); MBL deficiency and TNFA-308 associations were reviewed in PMID: 17804571. HGNC genes: HLA-DRB1, HLA-DQA1, HLA-DQB1, IGHV4-61, TNF, MBL2.

F006 — Streptococcal superantigens (SpeA) link pharyngitis to scarlet fever and subvert immunity; the M1UK clone is emerging

Streptococcal pyrogenic exotoxin A (SpeA) expression is epidemiologically linked to tonsillo-pharyngitis and scarlet-fever outbreaks. As a superantigen, SpeA drives massive tonsil T-cell proliferation with proinflammatory cytokine release, yet paradoxically causes B-cell apoptosis and abrogation of IgA/IgM/IgG production, subverting protective humoral immunity. The emergent M1UK variant (27 SNPs distinct from M1global) is characterized by increased speA expression and is driving surges in scarlet fever and invasive disease.

"Streptococcal pyrogenic exotoxin (Spe) A expression is epidemiologically linked to streptococcal tonsillo-pharyngitis and outbreaks of scarlet fever" — PMID: 30815853

"marked B cell apoptosis and abrogation of total immunoglobulin (Ig)A, IgM, and IgG production occurred in the presence of SpeA and other superantigens" — PMID: 30815853

"M1UK differs from progenitor M1global genotype by 27 single-nucleotide polymorphisms and is characterized by increased speA superantigen expression in vitro." — PMID: 39206960

Genomic surveillance in Shanghai documented a parallel rise in emm1 isolates carrying speA, speC, and spd1 virulence genes and ermB/tetM resistance determinants (PMID: 32562850). GO: GO:0050852 (T cell receptor signaling); GO:0006915 (apoptotic process).

F007 — Lewis rat autoimmune valvulitis (RAV) model recapitulates M-protein-driven rheumatic carditis

Immunization of Lewis rats with recombinant GAS M5 protein induces mitral valvulitis and myocarditis with CD3⁺/CD4⁺/CD68⁺ mononuclear infiltration of valve tissue and P-R-interval prolongation on ECG — features resembling human rheumatic carditis. Both anti-M5 antibodies and M5-specific T cells transfer carditis to naïve syngeneic rats, and repeat M-protein exposure exacerbates cardiac damage via an enhanced anti-cardiac-myosin antibody response. An M5 B-repeat peptide (aa 161–180) induces lymphocytes cross-reactive to cardiac myosin.

"serum plus in vitro expanded rM5-specific T-cells from hyperimmune rats were capable of transferring carditis to naïve syngeneic animals" — PMID: 31062619

"repetitive booster immunization with GAS-derived recombinant M protein (rM5) resulted in an enhanced anti-cardiac myosin antibody response that may contribute to the breaking of immune tolerance leading to RF/RHD" — PMID: 27562362

"Rats immunized with streptococcal M5 protein developed valvular lesions, distinguished by infiltration of CD3(+), CD4(+), and CD68(+) cells into valve tissue" — PMID: 19273562

This model directly demonstrates the molecular-mimicry mechanism (F002) is pathogenic and transferable. Detailed induction protocols are consolidated in PMID: 42261692. CL terms: CL:0000084 (T cell), CL:0000624 (CD4⁺ T cell), CL:0000235 (macrophage, CD68⁺).

F008 — GAS pharyngitis causes suppurative and non-suppurative complications; antibiotics reduce them

Suppurative complications (local spread) include peritonsillar/retropharyngeal abscess (quinsy), sinusitis, mastoiditis, otitis media, and rarely orbital cellulitis, meningitis, brain abscess, and intracranial venous sinus thrombosis. Non-suppurative (autoimmune) complications include ARF, APSGN, and neuropsychiatric sequelae (Sydenham chorea; the proposed PANDAS entity with anti-D1R dopamine-receptor autoantibodies targeting the basal ganglia). A Cochrane meta-analysis (27 trials, 2,835 cases) found antibiotics reduced acute otitis media (RR 0.30, 95% CI 0.15–0.58), quinsy, and ARF by more than two-thirds (RR 0.22, 95% CI 0.02–2.08).

"Complications associated to group-A streptococcal pharyingitis include non-suppurative complications such as acute rheumatic fever and glomerulonephritis and suppurative complications such as peritonsillar or retropharyngeal abscess, sinusitis, mastoiditis, otitis media, meningitis, brain abscess, or thrombosis of the intracranial venous sinuses." — PMID: 23067784

"Antibiotics reduced the incidence of acute otitis media (RR 0.30; 95% CI 0.15 to 0.58)" — PMID: 17054126

"Emerging molecular evidence identifies anti-D1R autoantibodies, acting via G protein-and beta-arrestin-mediated signalling, as candidate bi[omarkers]" — PMID: 42196589

The PANDAS/PANS construct remains controversial but biologically plausible; single-cell RNA-seq of a Sydenham chorea patient showed B-cell HLA-DR/DQ upregulation and plasma-cell proteasomal activation, supporting a B-cell-mediated autoantibody hypothesis (PMID: 40859454; PMID: 42603022). HP terms: HP:0000388 (otitis media), HP:0000246 (sinusitis), HP:0002072 (chorea for Sydenham).

F009 — GAS pili (T-antigen) mediate adhesion/colonization and are leading vaccine candidates

GAS pili are surface-exposed structures involved in adhesion and colonization; the major component is the T-antigen, which multimerizes to form the pilus shaft and is encoded in the FCT genomic region. A multivalent T-antigen fusion vaccine (TeeVax1–3; 18 T-antigens) produced opsonophagocytic, cross-reactive antibodies covering ~95% of 21 T-antigens and conferred protection against invasive disease in mice. Mucosal delivery of GAS pili via Lactococcus lactis generated neutralizing/opsonophagocytic antibodies and improved nasopharyngeal GAS clearance.

"Pili of Group A Streptococcus (GAS) are surface-exposed structures involved in adhesion and colonisation of the host during infection. The major protein component of the GAS pilus is the T-antigen, which multimerises to form the pilus shaft." — PMID: 33623073

"Combining TeeVax1-3 produced a robust antibody response in rabbits that was cross-reactive to a full panel of 21 T-antigens, expected to provide over 95% vaccine coverage." — PMID: 33623073

"intranasal immunisation of mice improved clearance rates of GAS after nasopharyngeal challenge" — PMID: 28775292

No licensed GAS vaccine yet exists; pilus/T-antigen and M-protein-based approaches are the leading strategies (PMID: 38543606). GO: GO:0009289 (pilus); GO:0007155 (cell adhesion).

F010 — The ARF sequela is diagnosed by the 2015 revised Jones criteria (AHA)

The 2015 AHA revision of the Jones criteria is the international gold standard for diagnosing ARF. It stratifies by population risk, offering two diagnostic pathways — prioritizing specificity in low-risk and sensitivity in moderate/high-risk populations — recommends Doppler echocardiography in all suspected/confirmed cases, and allows subclinical carditis to fulfill a major criterion. Evidence of antecedent GAS infection (elevated/rising ASO or anti-DNase B, or positive throat culture/RADT) is a required supporting criterion.

"update those criteria to also take into account recent evidence supporting the use of Doppler echocardiography in the diagnosis of carditis as a major manifestation of acute rheumatic fever" — PMID: 25908771

"the criteria consider the risk within a population and offer two separate diagnostic pathways that prioritise specificity among those at low risk and sensitivity among those at moderate/high risk" — PMID: 27326214

Lab biomarkers: anti-streptolysin O (ASO), anti-DNase B. Imaging: Doppler echocardiography.

F011 — APSGN presents as immune-complex nephritic syndrome with hypocomplementemia

APSGN is an acute autoimmune kidney condition triggered by pharyngitis or skin infection with specific nephritogenic S. pyogenes strains; it is the most common cause of pediatric acute glomerulonephritis globally. Children present with a nephritic picture: edema, painless hematuria, and hypertension. In a 100-child cohort, low serum C3 occurred in 93.5%, elevated anti-DNase B in 100%, and elevated ASO in 85%; biopsy showed post-infectious nephritis with immune-complex deposits (some crescentic). Treatment is largely supportive (managing hypertension/fluid overload). Incidence is strongly tied to childhood socioeconomic disadvantage and dropped after COVID-19 non-pharmaceutical interventions.

"Acute post-streptococcal glomerulonephritis (APSGN) is an acute autoimmune kidney condition triggered by skin infection or pharyngitis caused by specific strains of Streptococcus pyogenes (Group A streptococcus)." — PMID: 40174621

"Children typically present with a nephritic clinical picture: oedema, painless haematuria and hypertension." — PMID: 40174621

"C3 levels were low in 86/92 (93.5%) children; 94/94 (100%) children had elevated anti-deoxyribonuclease-B (anti-DNase-B) levels; and 80/94 (85%) also had elevated anti-streptolysin O titre (ASOT) at presentation" — PMID: 38170231

APSGN hospitalizations fell markedly after COVID-19 NPIs (PMID: 38688264); in Nepal, C3 was depressed in 61.9–100% of cases and pyoderma was the dominant preceding route (PMID: 40119285). An experimental rabbit study proposed that GAS IgG-binding surface proteins trigger anti-IgG immune-complex formation and glomerular deposition, offering a complementary (non-mimicry) pathogenic route for APSGN (PMID: 15676011). HP terms: HP:0000790 (hematuria), HP:0000969 (edema), HP:0000822 (hypertension), HP:0000093 (proteinuria); UBERON:0000074 (renal glomerulus).

F012 — Secondary benzathine penicillin G prophylaxis prevents progression of latent RHD (GOAL RCT)

The GOAL randomized controlled trial (Uganda; 916 children/adolescents aged 5–17 with echocardiographically confirmed latent RHD) compared intramuscular penicillin G benzathine every 4 weeks for 2 years versus no prophylaxis. Echocardiographic progression at 2 years was significantly lower in the prophylaxis arm, establishing that secondary antibiotic prophylaxis prevents progression of screen-detected latent RHD.

"Participants were randomly assigned to receive either injections of penicillin G benzathine (also known as benzathine benzylpenicillin) every 4 weeks for 2 years or no prophylaxis." — PMID: 34767321

"Rheumatic heart disease affects more than 40.5 million people worldwide and results in 306,000 deaths annually." — PMID: 34767321

Natural-history data show untreated moderate-to-severe latent RHD progresses in ~47.6% of cases, with younger age and morphological mitral-valve features as risk factors (PMID: 28972003). The GOAL protocol powered for a 50% relative risk reduction, randomizing 916 participants (PMID: 31301533). NCIT: benzathine benzylpenicillin (NCIT:C47476).

Mechanistic Model / Interpretation

Ordered causal chain

1. GAS is transmitted via respiratory droplets and CONTACTS pharyngeal epithelium.
2. Surface adhesins (M protein, pili/T-antigen, fibronectin-binding proteins)
   MEDIATE adhesion → LEADS TO colonization of the tonsillar/pharyngeal mucosa. [F001, F009]
3. Colonization + secreted toxins (streptolysins, SpeA superantigen, proteases)
   TRIGGER local innate inflammation → RESULTS IN the acute pharyngitis phenotype
   (fever, sore throat, tonsillar exudate, tender cervical nodes). [F001, F003, F006]
|
|-- BRANCH A (suppurative): unchecked local spread LEADS TO peritonsillar/
|   retropharyngeal abscess, otitis media, sinusitis, mastoiditis, and rarely
|   intracranial extension. [F008]
|
|-- BRANCH B (immune / non-suppurative):
    4B. Antigen presentation of streptococcal peptides (M protein, N-acetyl-
glucosamine) by susceptible HLA class II alleles (DRB1*07, DQA1/DQB1)
ACTIVATES cross-reactive CD4+ T cells and B cells. [F002, F005]
    5B. Molecular mimicry → cross-reactive antibodies + T cells RECOGNIZE
human cardiac myosin, valve endothelium, glomerular / neuronal antigens.
(Demonstrated & transferable in Lewis rat RAV model.) [F002, F007]
  |
  |-- Cardiac branch: valvulitis/carditis → RESULTS IN acute rheumatic
  |   fever → repeated exposure LEADS TO chronic rheumatic heart disease. [F007, F010, F012]
  |-- Renal branch: immune-complex deposition in glomeruli (nephritogenic
  |   strains) → RESULTS IN APSGN nephritic syndrome + hypocomplementemia. [F011]
  |-- Neuro branch (inferred/controversial): anti-neuronal / anti-D1R
      autoantibodies target basal ganglia → Sydenham chorea / PANDAS. [F008]

Upstream vs downstream

Layer Element Direction
Initiating lesion GAS adhesion/colonization of pharynx (M protein, pili) Most upstream [F001, F009]
Amplifier Superantigen (SpeA) T-cell activation; humoral subversion Upstream–mid [F006]
Gatekeeper Host HLA class II genotype (DRB1*07 susceptible; DRB1*15 protective) Determines whether Branch B proceeds [F005]
Effector (autoimmune) Cross-reactive antibodies + T cells vs cardiac myosin/valve/glomerulus/neurons Downstream [F002, F007, F011]
Clinical endpoint Pharyngitis (acute) → ARF/RHD, APSGN, chorea (weeks–years later) Terminal

Cell types and processes

Pharyngeal/tonsillar epithelial cells (CL:0000066) are the primary infection site; tonsillar CD4⁺ T cells (CL:0000624) and B cells (CL:0000236) mediate the superantigen response and autoimmunity; macrophages (CL:0000235, CD68⁺) and plasma cells infiltrate target tissues. Key GO biological processes: GO:0007155 (cell adhesion), GO:0050852 (TCR signaling), GO:0002250 (adaptive immune response), GO:0006956 (complement activation, APSGN), GO:0006915 (apoptosis, superantigen-induced B-cell death). Anatomy: UBERON:0006562 (pharynx), UBERON:0002372 (tonsil), UBERON:0002007 (heart valve), UBERON:0000074 (glomerulus), UBERON:0002420 (basal ganglia).

Evidence Base

PMID Role in report What it supports
27312939 Primary Pharynx as reservoir; adhesion/colonization as initiating steps (F001)
40572286 Primary GAS causes pharyngitis; triggers APSGN/ARF/RHD sequelae (F001, F002)
40484016 Primary ARF as autoimmune sequela evolving to RHD (F002)
41956705 Primary Treating pharyngitis reduces ARF 70–80% (F002)
37493159 Review Clinical phenotype; need for microbiological confirmation (F003)
39528865 Primary Centor score inadequate alone (F003)
38182052 Meta-analysis McIsaac/Centor equally ineffective for triage (F003)
34535115 Primary Cough/coryza rule out GAS; RADT+Centor PPV 93% (F003)
34805428 EHR cohort GAS vs non-group-A pharyngitis clinically indistinguishable (F003)
39259691 Review Universal penicillin susceptibility; macrolide resistance (F004)
33728634 Cochrane No antibiotic superior to penicillin; penicillin first-line (F004)
22691611 Guideline Amoxicillin dosing; macrolides for penicillin allergy (F004)
32967480 Meta-analysis HLA-DRB1*07 susceptible; DRB1*15 protective (F005)
31519994 GWAS review HLA-DQ + IGHV4-61 loci (F005)
37406855 Primary Twin concordance 19% vs 2.5% (F005)
16426242 Primary DRB1*13/DRB5*/DRB3* protective (F005)
17804571 Review TNFA-308, MBL deficiency, DR7-restricted M5 recognition (F005)
30815853 Primary SpeA links to pharyngitis/scarlet fever; B-cell apoptosis (F006)
39206960 Primary M1UK clone, 27 SNPs, increased speA (F006)
32562850 Primary emm1 rise, speA/speC virulence genes (F006)
31062619 Model organism M5 Ab/T cells transfer carditis (F007)
27562362 Model organism Repeat M-protein → anti-cardiac-myosin Ab (F007)
19273562 Model organism CD3/CD4/CD68 valve infiltration (F007)
23067784 Case/review Suppurative + non-suppurative complication list (F008)
17054126 Cochrane Antibiotics reduce otitis media RR 0.30 (F008)
42196589 Review Anti-D1R autoantibodies in PANDAS (F008)
40859454 scRNA-seq B-cell HLA-DR/DQ upregulation in Sydenham chorea (F008)
33623073 Primary Pili/T-antigen; TeeVax ~95% coverage (F009)
28775292 Model organism Mucosal pilus vaccine improves clearance (F009)
25908771 Guideline 2015 Jones criteria; echocardiography (F010)
27326214 Guideline Risk-stratified diagnostic pathways (F010)
40174621 Review APSGN definition + nephritic phenotype (F011)
38170231 Primary Lab frequencies: C3 low 93.5%, anti-DNase B 100% (F011)
15676011 Model organism IgG-binding proteins → immune complexes (APSGN/carditis) (F011)
34767321 RCT GOAL: BPG prevents latent RHD progression; 40.5M affected (F012)
28972003 Cohort Latent RHD natural history: 47.6% progression (F012)

Evidence-source mix: human clinical (guidelines, RCTs, cohorts, meta-analyses) dominates; model-organism data (Lewis rat RAV, mouse/rabbit vaccine and immune-complex studies) supports mechanism; in-vitro data (tonsil superantigen assays) and computational/genomic surveillance (M1UK, emm typing, GWAS) complete the picture.

Section-by-Section Coverage Notes

  • Etiology (2): Infectious cause = GAS (F001). Genetic risk modifiers are host HLA class II (F005) — these gate autoimmune sequelae, not primary infection. Environmental risk factors: crowding, school age (5–15 y), winter/early-spring seasonality, socioeconomic disadvantage (esp. APSGN/RHD). Gene–environment interaction: susceptible HLA + GAS exposure is required for ARF (F002, F005).
  • Phenotypes (3): Fever (HP:0001945), pharyngitis (HP:0025439), odynophagia/dysphagia (HP:0002015), tonsillar exudate, cervical lymphadenopathy (HP:0002751), palatal petechiae, scarlatiniform rash (scarlet fever). Childhood onset; mild–moderate, self-limited/episodic. Sequela phenotypes: carditis (HP:0001635), chorea (HP:0002072), hematuria (HP:0000790).
  • Genetic/molecular (4): No causal human gene (not Mendelian). Susceptibility loci: HLA-DRB1, HLA-DQA1/DQB1, IGHV4-61, TNF, MBL2 (F005). Pathogen genetics: emm/M-protein types, speA, M1UK 27-SNP variant (F006).
  • Environmental (5): Respiratory droplet transmission; crowding; infectious agent NCBITaxon:1314. No toxin/occupational etiology.
  • Anatomy (7): Primary — pharynx/tonsils (UBERON:0006562, UBERON:0002372); epithelial tissue. Secondary — heart valves (mitral > aortic), renal glomeruli, basal ganglia, middle ear/sinuses.
  • Temporal (8): Acute onset; self-limited over ~1 week. ARF latency ~2–4 weeks post-pharyngitis; APSGN ~1–2 weeks (throat) / 3–6 weeks (skin); RHD develops over years with recurrent infection.
  • Epidemiology (9): GAS pharyngitis is among the most common outpatient infections; ~15–30% of pediatric sore throats. Not inherited (polygenic host susceptibility for sequelae). RHD >40.5M prevalent, ~306,000 deaths/yr (F012), concentrated in low/middle-income countries and Indigenous populations.
  • Diagnostics (10): RADT/culture/molecular throat swab (F003); ASO & anti-DNase B serology (retrospective); C3 for APSGN (F011); Doppler echocardiography for ARF/RHD (F010). No genetic/omics diagnostics in routine use.
  • Prognosis (11): Acute pharyngitis excellent (self-limited). RHD is the principal mortality driver. APSGN generally favorable short-term renal outcome in children.
  • Treatment (12): Penicillin V / amoxicillin first-line (10-day course); benzathine penicillin G for adherence and secondary prophylaxis; macrolides/cephalosporins for penicillin allergy (F004). Supportive analgesia/antipyretics. No gene/cell/RNA therapies applicable.
  • Prevention (13): Primary — treat pharyngitis to prevent ARF (F002); community programs (PMID 41956705). Secondary — 4-weekly benzathine penicillin G prevents latent RHD progression (GOAL RCT, F012). No licensed vaccine; T-antigen/pilus and M-protein candidates in development (F009).
  • Other species / models (14–15): GAS is a human-restricted pathogen; the Lewis rat autoimmune valvulitis model and mouse nasopharyngeal-challenge / rabbit immune-complex models are the principal experimental systems (F007, F009, F011).

Limitations and Knowledge Gaps

  1. No licensed human GAS vaccine. T-antigen (TeeVax) and M-protein candidates show promise in animal models (F009), but human efficacy, safety (avoiding autoimmune cross-reactivity), and broad strain coverage remain unproven.
  2. PANDAS/PANS remains contested. The anti-D1R/anti-neuronal autoantibody mechanism and even the diagnostic entity are supported by translational and single-cell data (F008) but lack universally accepted, reproducible biomarkers.
  3. Host-genetics effect sizes are modest. HLA associations (OR ≈ 1.68 for DRB1*07) explain only part of susceptibility; GWAS in ARF/RHD are still emerging and underpowered outside a few populations (F005).
  4. Quantitative ARF-prevention estimate rests on a single Cochrane analysis with a wide CI (RR 0.22, 95% CI 0.02–2.08) because ARF is now rare in high-income trial settings (F008); most trials were not conducted where complication risk is highest.
  5. Animal models are imperfect. The Lewis rat reproduces valvulitis/carditis but not the full spectrum (chronic scarring, chorea, glomerulonephritis) of human disease, and no model recapitulates natural pharyngeal transmission-to-sequela progression.
  6. Molecular-profiling gaps: limited human transcriptomic/proteomic/metabolomic signatures of acute pharyngitis specifically (as opposed to invasive GAS or RHD tissue).
  7. Strain–sequela specificity (nephritogenic vs rheumatogenic emm types) is described but not mechanistically resolved.

Proposed Follow-up Experiments / Actions

  1. Advance a multivalent GAS vaccine combining T-antigen (TeeVax) and conserved M-protein epitopes toward controlled human infection / phase-appropriate trials, with rigorous screening for cardiac-myosin cross-reactivity before human dosing (extends F007, F009).
  2. Single-cell + spatial transcriptomics of tonsillar tissue during acute GAS pharyngitis vs viral pharyngitis, to map the epithelial–immune interface and superantigen-driven T/B-cell dynamics (extends F006).
  3. Prospective HLA-genotyped cohort linking pharyngitis episodes to ARF/APSGN outcomes to refine risk stratification (validate DRB1*07/DRB1*15 and DQ/IGHV4-61; F005) and enable precision secondary prophylaxis.
  4. Define serum/CSF autoantibody panels (anti-cardiac-myosin, anti-D1R, anti-lysoganglioside) with standardized assays to test PANDAS/Sydenham diagnostic reproducibility (F008).
  5. Scale echocardiographic screening + benzathine penicillin G programs in endemic regions, building on GOAL to define cost-effectiveness and adherence-support models (F012).
  6. Molecular surveillance of M1UK and emm1/emm12 clones with paired virulence-gene and antimicrobial-resistance profiling to anticipate scarlet-fever/invasive-disease surges (F006).
  7. Nephritogenic-strain mechanistic studies to identify the specific streptococcal antigen(s) (e.g., NAPlr, SpeB, IgG-binding proteins) driving immune-complex glomerulonephritis and to explain throat- vs skin-route differences (F011).

Report compiled from 12 confirmed findings and 55 reviewed papers across 5 investigation iterations. Evidence quotes are verbatim from cited PubMed abstracts.

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.3.0rc3.

Outcome Count
References checked 43
Resolved 43
Unresolved (possible confabulation) 0
Unverifiable 0
Quoted claims checked 1
Quoted claims found in source 1
Quoted claims not found in source 0
References weighed for topical relevance 43
On topic 30
Off topic 0

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome Count
Terms checked 37
Resolved 37
Unresolved (possible confabulation) 0
Obsolete 0
Unverifiable 0
Terms whose name was checked 32
Terms named correctly 18
Terms named as a different term 5
Terms whose name is worth a second look 9

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

  • MONDO:0021783 (2 mentions) - the report calls it "Mondo"; MONDO calls it streptococcal sore throat
  • MONDO:0005295 (1 mention) - the report calls it "rheumatic heart disease"; MONDO calls it intermittent vascular claudication
  • UBERON:0002007 (2 mentions) - the report calls it "heart valve"; UBERON calls it medulla of lymph node
  • NCIT:C61785 (1 mention) - the report calls it "Penicillin"; NCIT calls it Hydrocortisone Acetate
  • NCIT:C287 (1 mention) - the report calls it "Amoxicillin"; NCIT calls it Aspirin

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

  • NCBITaxon:1314 (2 mentions) - the report calls it "S. pyogenes"; NCBITaxon calls it Streptococcus pyogenes
  • GO:0050852 (2 mentions) - the report calls it "T cell receptor signaling", "TCR signaling"; GO calls it T cell receptor signaling pathway, and lists "TCR signaling pathway" among its other names
  • GO:0006915 (2 mentions) - the report calls it "apoptotic process", "apoptosis, superantigen-induced B-cell death"; GO calls it apoptotic process, and lists "apoptotic programmed cell death" among its other names
  • CL:0000624 (2 mentions) - the report calls it "CD4⁺ T cell", "CD4⁺ T cells"; CL calls it CD4-positive, alpha-beta T cell
  • CL:0000235 (2 mentions) - the report calls it "macrophage, CD68⁺"; CL calls it macrophage
  • HP:0002072 (2 mentions) - the report calls it "chorea for Sydenham"; HP calls it Chorea, and lists "Choreiform movements" among its other names
  • UBERON:0000074 (2 mentions) - the report calls it "glomerulus"; UBERON calls it renal glomerulus, and lists "glomerulus" among its other names
  • GO:0006956 (1 mention) - the report calls it "complement activation, APSGN"; GO calls it complement activation
  • UBERON:0002420 (1 mention) - the report calls it "basal ganglia"; UBERON calls it basal ganglion, and lists "basal ganglia" among its other names

Terms named inconsistently

The report gives these identifiers more than one name of its own:

  • CL:0000066 - called "epithelial cell", "epithelial cells"
  • GO:0050852 - called "T cell receptor signaling", "TCR signaling"
  • GO:0006915 - called "apoptotic process", "apoptosis, superantigen-induced B-cell death"
  • CL:0000624 - called "CD4⁺ T cell", "CD4⁺ T cells"